TQH3906

· Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TQH3906, covering 2025-01-01 to 2026-04-03. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus [Phase 2]